August 21 news reporters from the General Administration of Food and Drug Administration official website learned that 9 enterprises produced 9 batches of Chinese medicine tablets tested unqualified.
Among them, marked as Luzhou City, Shanghai Pharmaceutical Co., Ltd., Jiangxi Bairen Chinese Medicine Tablets Co., Ltd., Hubei Yuanzhi Pharmaceutical Co., Ltd., Hainan Shounanshan Ginseng Co., Ltd., Sichuan Qianfang Chinese Medicine Drink Tablets Co., Ltd. and other enterprises produced 6 batches of Yuanzhi unqualified. The nonconforming item is aflatoxin.
marked as Beijing Tongrentang (Yuzhou) drink tablets limited liability company, Henan Juren Chinese medicine drink tablets Co. , Ltd. and other enterprises produced 3 batches of Yuanzhi (making Yuanzhi) unqualified. The nonconforming item is aflatoxin.
the health hazard aflatoxin enters the body, it is metabolized mainly under the role of the hepatocellular endosome microsome hybrid functional oxidase system. Aflatoxin is non-carcinogenic without metabolic activity, because the sleeve of quiculhotoxin is called pre-carcinogens, far higher than the toxicity of cyanide, arsenide and organic pesticides, of which B1 is the most toxic. Acute poisoning can occur when a person's intake is high, and acute hepatitis, hemorrhagic necrosis, hepatocellular fat degeneration and bile tube growth can occur. When micro-continuous intake, can cause chronic poisoning, growth disorders, causing fibropathy, resulting in the growth of fibrous tissue. AFT also has the highest carcinogenicity and is one of the strongest known carcinogens.
the above-mentioned non-conforming Chinese medicine tablets, the relevant provincial (city) Food and Drug Administration has taken seizure and other control measures, requiring enterprises to suspend the sale of the use, recall products, and carry out rectification.
The State Administration of Food and Drug Administration requires the Food and Drug Administration of the province (city) where the relevant units are located to investigate the illegal acts of producing and selling unqualified drugs in accordance with Articles 73, 74 and 75 of the Drug Administration Law of the People's Republic of China, and to make public the results of the treatment of the units involved in the production and sale of unqualified drugs within three months, and to report the relevant information in a timely manner.
In the investigation work, if an enterprise has any objection to the authenticity of the product, it may submit to the Food and Drug Administration of the province (city) where it is located, and the local provincial (city) Food and Drug Administration shall investigate and verify the production and sales of the enterprise and inform the Food and Drug Administration of the province (city) where the sampling unit is located. The Food and Drug Administration of the province (city) where the sampling unit is located shall immediately file a case for investigation and trace the source of the product after receiving a notification of objection to the authenticity of the non-conforming product. If it is indeed the production of the marked production enterprise, the relevant provincial (city) Food and Drug Administration shall severely punish the production enterprise. (CCTV)